%PDF-1.4
%
4 0 obj
<>
endobj
5 0 obj
<>stream
Eberwein P.; Krösser S.; Steven P.
Semifluorinated Alkane Eye Drops in Chronic Ocular Graft-versus-Host Disease: A Prospective, Multicenter, Noninterventional Study
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.<br />
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.<br />
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Purpose: Ocular graft-versus-host disease (oGvHD) following allogeneic hematopoietic stem cell transplantation develops as severe dry eye disease (DED) and is initially treated with lubricants, although no clinical trials are available using artificial tears in oGvHD. This trial was set up to test perfluorohexyloctane (NovaTears®) as nonpreserved layer-forming agent for the treatment of DED in oGvHD. Methods: 25 patients with severe DED due to oGvHD received 1 drop perfluorohexyloctane 4 times daily during a prospective, multicenter, observational 12-week study on top of established topical therapy. Clinical parameters included Schirmer test, tear film breakup time, corneal staining, meibum secretion and ocular surface disease index. Adverse events, visual acuity and intraocular pressure were key safety parameters. Results: From 25 patients recruited, 23 presented for the second visit. Perfluorohexyloctane treatment did not lead to any changes in clinical or safety parameters but led to fast relief in symptoms in 57% of the patients. One adverse reaction occurred. Conclusions: This study showed no change in clinical signs in severe DED due to oGvHD, which was not unexpected due to the underlying pathomechanisms. However, the study showed improvement of symptoms in individual patients allowing application of perfluorohexyloctane as an additional symptomatic therapy in oGvHD.
Ocular graft-versus-host disease
Semifluorinated alkanes
Perfluorohexyloctane
Aqueous deficiency
Dysfunctional tears syndrome
endstream
endobj
6 0 obj
<>stream
x+ |
endstream
endobj
7 0 obj
<>stream
x}M@+X]ׯ[Q:Ht4RT
}nHTBBnc܃F(;`Ӗd,cQ D؋3Ю}Ked22i^
1!bv9^Ϧa{v`6m=CR.|I=C#a"/ukE1O%~>
endstream
endobj
8 0 obj
<>stream
x+ |
endstream
endobj
9 0 obj
<>stream
x}M@+X]ׯ[Q:Ht4RT
}nHTBBnc܃Pv-RY&ԉg]U8 ileMeҼ!b[C
9zsMUþt?Fgm{˩ \zH.GE,_֊$c)>
endstream
endobj
10 0 obj
<>stream
x+ |
endstream
endobj
11 0 obj
<>stream
x}M@+X]ׯ[Q:Ht4RT
}nHTBBnc܃M[LG%a/ B&q,A Ғ<ʤyC60Wfrx=}E~ڴ)S?H(%.],1#XlԭI<->
endstream
endobj
12 0 obj
<>stream
x+ |
endstream
endobj
13 0 obj
<>stream
x}M@+Xp]Vԭ]5ͶԥU
}nHTBnc[rLB/N!&nU9*lemm, [sCzsMv`s~31SN0Pgİ~[+y22>
endstream
endobj
14 0 obj
<>stream
x+ |
endstream
endobj
15 0 obj
<>stream
x}M@+Xpu[Q:Ht4RT
}nHTBncPvK[vLA/NAFQ>ʦyC60ח$z{mUþ1L?dm{KO9G<>>#T%11Q~[ky6n>
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
x}0}=ꁲm)7@W*DK 11Qw6l X5Y1dQ L`]U{86A &y֥I>stream
x+ |
endstream
endobj
19 0 obj
<>stream
x}0}=ꁲm)7@W*DK 11Qw6l8-Aj
Tc(ԙ B"pl* Mf+Kfy>1Pȩ/&nיb
~M6ؤMH@E@/tyrd0QbnH2h?5
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
x}0}=ꁲm)7@W*DK 11Qw6l<(Z`dPG%3aAvUETHVY&}su}c?S_Lܮ3ŔkțVw=lI~r932_R"`1KZd?9
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
x}0}=JFoz +
bh,DK 11Qw6lMC([DɖhPB3BLܪsKf+l*E>1Pp'nיb~]}0S?3.1
x |(IOH헺B?=
endstream
endobj
25 0 obj
<>stream
HWێ8}Vt,2`wƀh3萒)^d]A[YdU:u_lkbM>>?iIBKޮj~_F9Q,6/تyoV<|Z=|!(NludI%"EDy9|Ȟ'>ad>9M&Dgad%-e QN;&{;QN1وc|lx'K0aN=h`..sGdkWo6kTY_~XMrU+K{K%w0#p(q(|\M';
n]O6wꈝ%^~'Z՝ndOV,WL80UVIJ! HEųEi#x1YnF 1?/kJHs$ WP"dw!ōhF5\T ׆#`7d-)m56DGVV"- l}U3oSnqv@N*Ԭ!*wmXOhakbˁQjD m0ec/rf_s(N>
U+BւWݲFtֲT`^v'js$~Ls'/Vpw\Vt.jv·&<ϲA:qَ6rZsgroD!Nv厷X)h˺'
32Mј_o+Z 8|w}%X9{~2eIrNtHZֆ^jmgribbߊ岾\ݬ^-eNSѽŭT" _c٧*k&l:E-D&|(d=RC?J[ܓ=ɿoEu/9/Bm7mT&Qݸd(ZG5fyF N^OU@aɠ
ݒ0(Re1G%xGEvw ݁*mzF>-rps[,J.Rp=n*,zӃZ2A߉bAq)ģb{FlN
JzߟlN㿜S$'EIyNn%2t~"DV'ǎZL/)Oedl21ho@[a %jF'lZ_XЭR,EaW㰻 ddE1:wsgRuH#堾#eJPك:G
˗K8M|˱r<CP.2P$\t |,dkjbtzaLzX0cKC'YQO/"ՋkӁ0(Z^ئ5Y.3}qGDJ1x1:RlK))i2>i2)}1;;k8e6=d^QcMt,j$-4Jl|/HIq_lڌP)(+LЌL^pp"[>R{kʾ&XS*ܠ:
u!%9=Vd{7uډZ7ud=o߽{SAO?O߿~y+~wYk*6ET2yL`4y4-~n_xE"MY:[j4_BH}AQbŬ߲"ٯ040̒A=ЙDÞs ̥'cv]NbEYn 8h6{ZD
@V4V;A{ FiB2)T9ע3oϘh;kAª$_$' NA ZZ\,wT=n4w$